摘要
目的探究齐拉西酮注射序贯疗法治疗精神分裂症急性期兴奋激越症状的临床疗效。方法选取2019年2月至2021年2月于本院接受治疗的88例急性期兴奋激越症状的精神分裂症患者作为研究对象,其中2019年2月至2020年2月收治的50例患者纳入观察组,采用齐拉西酮注射治疗后序贯口服齐拉西酮疗法;将2020年3月至2021年3月收治的38例患者纳入对照组,采用经齐拉西酮注射治疗后序贯口服奥氮平治疗,比较两组阳性与阴性症状量表(PANSS)评分、社会功能缺陷筛查量表(SDSS)、简易精神病反应量表(BPRS)评分、临床疗效及不良反应发生情况。结果两组PANSS总分、阳性评分、阴性评分及SDSS评分组间、时间和交互比较差异有统计学意义(P<0.05)。组内比较:两组治疗后各时间点PANSS总分、阳性评分、阴性评分及SDSS评分均低于前一时间点(P<0.05)。组间比较:治疗前,两组PANSS总分、阳性评分、阴性评分及SDSS评分比较差异无统计学意义;观察组治疗后各时间点PANSS总分、阳性评分、阴性评分及SDSS评分均低于对照组,差异有统计学意义(P<0.05)。两组BPRS评分组间、时间和交互比较差异有统计学意义(P<0.05)。组内比较:两组治疗后各时间点评分均显著低于前一时间点(P<0.05)。组间比较:治疗前,两组BPRS评分比较差异无统计学意义;观察组治疗后各时间点BPRS评分均低于对照组(P<0.05)。两组治疗总有效率比较差异无统计学意义。治疗1年内,观察组体质量增加、嗜睡、血糖血脂异常、锥体外系反应发生率均低于对照组,差异有统计学意义(P<0.05),两组QTc延长发生率比较差异无统计学意义。结论齐拉西酮注射序贯疗法治疗精神分裂症急性期兴奋激越症状疗效显著,能改善患者临床症状,降低不良反应发生率,安全性高,值得临床推广应用。
Objective To explore the clinical efficacy of ziprasidone injection sequential oral therapy in the treatment of excitatory agitation in acute phase of schizophrenia.Methods 88 patients with excitatory agitation in acute phase of schizophrenia who receivedtreatment in our hospital from February 2019 to February 2021 were selected as the study subjects.Among the patients,50 cases admitted from February 2019 to February 2020 were included in the observation group and were given sequential oral ziprasidone therapy after ziprasidone injection,and 38 cases admitted from March 2020 to March 2021 were included in the control group and treated with sequential oral olanzapine therapy after ziprasidone injection.positive and negative symptom scale(PANSS)scores,social disability screening scale(SDSS)score,brief psychiatric rating scale(BPRS)score,clin-ical efficacy and occurrence ofadverse reactions were compared between the two groups.Results There were significant differences in total PANSS scores,positive scores,negative scores and SDSS between the two groups of group,time points and interaction(P<0.05).Comparison within groups:total PANSS scores,positive scores,negative scores and SDSS scores of the two groups were lower than those of the previous time point af-ter treatment(P<0.05).Comparison between groups:before treatment,there were no significant differences in total PANSS scores,positive scores,negative scores and SDSS scores between the two groups;total PANSS scores,positive scores,negative scores and SDSS scores in the observation group were lower than those in the control group at all time points after treatment,and the differences were statistically significant(P<0.05).There were significant differences in BPRS scores between the two groups of group,time points and interaction(P<0.05).Comparison within groups:the scores of each time point after treatment were significantly lower than those of the previous time point(P<0.05).Comparison between groups:be-fore treatment,there was no significant difference in BPRS score between the two groups;the BPRS score in the observation group was lower than that in the control group at all time points after treatment(P<0.05).There was no significant difference in the total effective rate between the two groups.Within 1 year of treatment,the incidencerates of weight gain,lethargy,abnormal blood glucose and lipids and extrapyramidal reaction in the observation group were lower than those in the control group(P<0.05),but there was no statistically significant difference in the incidence of QTc prolongation between the two groups.Conclusion Ziprasidone injection sequential oral therapy has significant efficacy in the treatment of excitato-ry agitation in acute phase of schizophrenia,and it can improve the clinical symptoms and reduce the incidence of adverse reactions of patients,and has high safety,which is worthy of clinical promotion and application.
作者
胡玮
漆灵霞
黄洋
HU Wei;QI Lingxia;HUANG Yang(Department of Ward One,Jiangxi Mental Hospital,Nanchang,Jiangxi,330000,China)
出处
《当代医学》
2023年第22期84-87,共4页
Contemporary Medicine
关键词
精神分裂症急性期
激越
齐拉西酮
序贯口服疗法
Acute phase of schizophrenia
Agitation
Ziprasidone
Sequential oral therapy
